Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 7/20 | 0.56 |
| ▸ | NFE2L2 | Q16236 | 7/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 5/20 | 0.48 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.47 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16557592 | 0.92 | KEAP1 (0.59) | KEAP1NFE2L2TSHRPOLBMAPT | |
| SCHEMBL15583910 | 0.89 | MAPT (0.62) | KEAP1NFE2L2TSHRPOLBMAPT | |
| SCHEMBL16557451 | 0.88 | POLB (0.52) | KEAP1NFE2L2POLBMAPTHPGD | |
| SCHEMBL16557608 | 0.88 | KEAP1 (0.61) | KEAP1NFE2L2POLBMAPTHPGD | |
| SCHEMBL16557594 | 0.85 | KEAP1 (0.75) | KEAP1NFE2L2 | |
| SCHEMBL16557604 | 0.84 | KEAP1 (0.57) | KEAP1NFE2L2TSHRPOLBMAPT | |
| SCHEMBL16557607 | 0.84 | KEAP1 (0.57) | KEAP1NFE2L2POLBMAPTHPGD | |
| SCHEMBL15583928 | 0.83 | TSHR (0.66) | KEAP1NFE2L2TSHRPOLBMAPT | |
| SCHEMBL16557433 | 0.80 | POLB (0.54) | KEAP1NFE2L2POLBHPGD | |
| SCHEMBL16557450 | 0.80 | POLB (0.53) | KEAP1NFE2L2TSHRPOLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9790233-B2 | Compositions and methods of modulating 15-PGDH activity | CASE WESTERN RESERVE UNIVERSITY (US) | 2017-10-17 | — | — | US | disclosed |
| US-20170165241-A1 | COMPOSITIONS AND METHODS OF MODULATING 15-PGDH ACTIVITY | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2017-06-15 | — | — | US | disclosed |
| US-20150072998-A1 | COMPOSITIONS AND METHODS OF MODULATING 15-PGDH ACTIVITY | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2015-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170165241-A1 | COMPOSITIONS AND METHODS OF MODULATING 15-PGDH ACTIVITY | PTGS1, HPGD, PTGIS | KEAP1 882/4885NFE2L2 613/4885TSHR 3873/4885 |
| US-20150072998-A1 | COMPOSITIONS AND METHODS OF MODULATING 15-PGDH ACTIVITY | PTGS1, HPGD, PTGIS | KEAP1 882/4885NFE2L2 613/4885TSHR 3873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.